Talk to a Concierge  →
Home  ›  Related Resources  ›  Cancer Hospital Chinese Academy of Medical Sciences  ›  Stage III lung cancer trial
Clinical Research · English Editorial Summary

A chemo-free regimen kept stage III EGFR-mutant lung cancer in check 4.6 times longer than chemoradiotherapy

In the ADVANCE phase 3 trial led by Wang Lühua and Bi Nan's radiation oncology team, a fully oral regimen of the EGFR-targeted drug aumolertinib combined with radiotherapy kept disease from progressing for a median of 34.0 months, against 7.4 months for standard chemoradiotherapy.

Original report: 26 September 2026English summary: 6 October 2026Source: Zhuanhua Medical Network via Tencent NewsEdited by Wellward China
Cancer Hospital Chinese Academy of Medical SciencesBeijingCancer & TumorsLung cancerEGFR mutationRadiotherapyPhase 3 trial
Source and editorial note: This is an original English summary based on Zhuanhua Medical Network's Chinese-language report (via Tencent News), published 26 September 2026. It is not a full translation or an independent clinical assessment. The original source is the authority for the underlying report.
The study

A chemo-free answer for a neglected group

Roughly 25–30% of non-small cell lung cancers are diagnosed at stage III, where the tumour cannot be removed surgically but has not yet spread widely. Standard treatment is chemoradiotherapy followed by immunotherapy — but for the 10–20% of stage III patients whose tumours carry an EGFR mutation, immunotherapy works poorly, and several thousand such patients are diagnosed in China each year.

Landmark trials such as LAURA showed that giving a third-generation EGFR-targeted drug after chemoradiotherapy improves progression-free survival. The team behind the new study asked a different question: why keep the chemotherapy at all?

What the trial did

ADVANCE was a multicentre, randomised, open-label phase 3 trial led by Professor Wang Lühua — president of the Cancer Hospital CAMS Shenzhen hospital and a national authority in radiation oncology — together with Professor Bi Nan, head of thoracic radiotherapy at the Beijing campus. Patients took aumolertinib alone for nine weeks to shrink the tumour, received radiotherapy while continuing the drug, then kept taking it as consolidation: an entirely oral, chemotherapy-free sequence. The control arm received standard platinum-based chemoradiotherapy. The trial was stopped early after 43 patients were randomised, because an interim analysis showed a large difference between the groups.

Key results (median follow-up 25.5 months)

Median progression-free survival was 34.0 months with the chemo-free regimen versus 7.4 months with chemoradiotherapy — a hazard ratio of 0.15, with 24-month progression-free survival of 59.4% versus 0%. Overall survival showed a favourable trend, reaching statistical significance in the predefined "LAURA-like" subgroup. No grade 4–5 events occurred in the trial arm; neutropenia and nausea were significantly more frequent in the chemotherapy arm. Induction shrank tumours by about 22% on average, allowing smaller, less toxic radiation fields without loss of local control.

Evidence status: promising, but small and unblinded

Forty-three patients is a small trial, it was open-label, and it ended early — so the magnitude of benefit should be read with care. The authors support their case with a real-world cohort of seven centres in which TKI-containing regimens were independent predictors of both progression-free survival (HR 0.22) and overall survival (HR 0.23). Confirmation in larger trials is the natural next step.

Why it matters

For stage III EGFR-mutant lung cancer, ADVANCE is the first phase 3 evidence for a chemotherapy-free strategy, and it reframes the targeted drug as both a radiosensitiser and a controller of microscopic disease. For patients, the promise is an effective treatment without hospital-based chemotherapy cycles. This summary belongs to Wellward China's Cancer & Tumors health area; it describes research evidence, not advice for any individual's treatment.